Pharmacy Practice

Associate Professor
Focus: Cardiology/Anticoagulation

Contact Information
(518) 694-7187


Speaker Request
Katherine P. Cabral, PHARM.D., BCPS, BCCP, AACC


  • PGY-2 - Cardiology Specialty Residency, Boston Medical Center, Boston MA
  • PGY-1 - Pharmacy Practice Residency, Boston Medical Center, Boston MA
  • Pharm.D., Northeastern University, Bouve College of Health Sciences, Boston MA


  • PTPM Cardiovascular module
  • Advanced Pharmacy Practice Experience – Cardiology
  • Residency Prep Elective
  • Integrated Problem Solving (IPS) Workshop 4




  • Antithrombotic therapies
  • Heart Failure therapy
  • Role of a clinical pharmacist in ambulatory cardiology care
  • Acute coronary syndromes pharmacotherapy
  • Heparin induced thrombocytopenia



Plumadore E, Lombardo L, Cabral KP. Pharmacotherapy Review: Expanding Treatment Modalities in Transthyretin Cardiac Amyloidosis. Am J Health Syst Pharm 2022;79:52-62.

Padala SK, Lavelle MP, Sidhu MS, Cabral KP, Morrone D, Boden WE, Toth PP. Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review. J Card Pharm Ther Nov 2017;22(6):499-510.

Boden WE, Padala SK, Cabral KP, Buschmann I, Sidhu MS. The Role of Short-Acting Nitroglycerin in the Management of Ischemic Heart Disease. Drug Design, Development and Therapy 2015; 9:4793-4805.

Cabral KP, Ansell JE. The Role of Factor Xa Inhibitors in VTE Treatment. Vasc Health Risk Manag Jan 2015; 11:117-123.

Cabral KP. Pharmacology for the New Target-Specific Oral Anticoagulants. J Thromb Thrombolysis 2013; 36(2):133-140.

Croft PE, Cabral KP, Strout TD, Baumann MR, Gibbs MA, DeLaney MC.  Managing Blunt Trauma in Patients on Dabigatran Etexilate: Case Study and Review of the Literature. J Emerg Nursing 2013; 39(3):302-308.

Cabral KP, Fraser GL, Duprey J, Gibbons BA, Hayes T, Florman JE, Seder DB. Prothrombin Complex Concentrates to Reverse Warfarin-Induced Coagulopathy in Patients with Intracranial Bleeding. Clin Neuro Neurosurg 2013 Jun; 115(6):770-4.

Mantha S, Cabral KP, Ansell JA. New Avenues for Anticoagulation in Atrial Fibrillation. Clin Pharm Ther 2013; 93(1):68-77.

Cabral KP, Ansell JA. Oral Direct Factor Xa Inhibitors for Stroke Prevention in Atrial Fibrillation. Nat Rev Cardiol 2012; advance online publication 2.28.12; doi:10.1038/nrcardio.2012.19.

Runyan CL, Cabral KP, Riker RR, et al. “Bivalirudin Doses Correlate with Creatinine Clearance During Treatment of Heparin- Induced Thrombocytopenia: A Retrospective Chart Review.” Pharmacotherapy 2011: Pharmacotherapy 2011;31(9):850-856. 

Cabral KP, Ansell JA. Oral Direct Factor Xa Inhibitors for Stroke Prevention in Atrial Fibrillation. Nat Rev Cardiol 2012; 9:385-391. doi:10.1038/nrcardio.2012.19

Rolfe S, Papadopoulos S, Cabral KP. “Controversies of Anticoagulation Reversal in Life Threatening Bleeds.” J Pharm Pract 2010; 23: 217-225. 

Phillips KW, Ansell JA. “The Clinical Implications of New Oral Anticoagulants: Will the Potential Advantages be Achieved?” Thromb Haemost 2010;103:34-39. Cabral, KP. "How to meet national quality initiatives: best practices.” J Thromb Thrombolysis2009; 29(2): 105. 

Phillips KW, Dobesh PP, Haines ST. “Considerations in Using Anticoagulant Therapy in Special Patient Populations” AJHP 2008; 65 (suppl 7):S13-21. 

Phillips KW, Merli G.  “Chapter 10: Developing an Inpatient Anticoagulation Service”Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines. 3rdedition. Wolters Kluwer Health, Inc.: 2009


Garrison GD, Bidell M, Cabral K, Silvestro L, Boire A, Strang AF. Interdisciplinary Formative Assessments to Foster Student Learning in the Dual-Campus Large Classroom Setting (School Poster). AACP Annual Meeting, Boston MA, July 21-23, 2018.

Decina L, Parsels K, Cabral K. The Implementation of Pharmacy Consult Services in Lipid Management with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. NYS American College of Clinical Pharmacy Meeting, November 2, 2018.